Do you think there will be a role for duvelisib in the treatment of relapsed/refractory chronic lymphocytic leukemia?
Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to get started especially in our very old patients.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center
Answered on
I believe this agent could find a home for therapy in CLL as it is given by itself provided that further efficacy is demonstrated in a population where it would be most likely used, ibrutinib resistant CLL. Additionally, incorporation into non-BTK inhibitor combinations would also be possible. Given...
Join for free or sign in to see the full answer